Introduction
Reconstitution of the immune system after allogeneic stem cell transplantation (SCT) depends on the conditioning regimen before SCT, graft-versus-host disease (GVHD) and time after SCT. 1, 2 Parts of the innate immune system, such as granulocytes, monocytes and NK cells, recover within 2-6 months after SCT. 3 Patients who develop chronic GVHD after SCT may never recover normal immune function. 4 After SCT, the reconstitution of the B-cell repertoire is often delayed because of complications associated with GVHD, age and infections. 5, 6 Normal B-cell counts are reached between 6 and 9 months after SCT and after more than 12 months if GVHD has occurred. 7 Antibody production is also impaired after SCT. Serum IgM levels return to normal usually within 3-6 months, whereas recovery of serum IgG levels may be delayed up to one year or longer. 4, 7 Impairment of antibody immunity correlates with an increased risk of infections after SCT primarily due to encapsulated bacteria. 8, 9 In a randomized trial of long-term administration of intravenous immunoglobulin (IVIG), no differences in chronic GVHD or infections were shown between patients receiving IVIG and controls; 9 however, in this study patients with IgGo4 g/l received IVIG even if randomized to the control arm. It has also been suggested that immunization of the recipient and the donor before SCT may improve antibody immunity after SCT. 10, 11 In this study, we evaluated the clinical influence of IgG levels after SCT in 179 patients who received transplants between 1995 and 2002. This study evaluates the influence of IgG levels on incidence of infections, transplant-related mortality (TRM), and survival.
Patients and methods

Patients
This study retrospectively examines 179 consecutive patients who had undergone allogeneic SCT at Karolinska University Hospital Huddinge between 1995 and 2002. The ethical committee at the Karolinska Institute (Karolinska University Hospital Huddinge) approved all aspects of this study. Only patients with at least two IgG levels measured during the first 12 months were included in the study. This study excluded patients with myeloma, patients treated with IVIG and children younger than 10 years. Our experience is that the ability to produce IgG in children younger than 10 years can be very diverse and therefore difficult to evaluate. The indications for transplantation included acute leukemia (n ¼ 83), chronic leukemia (n ¼ 53), solid tumor (n ¼ 11), other malignancies (n ¼ 16) and non-malignant disease (n ¼ 16). Table 1 summarizes the patients' demographics.
Donors and tissue typing
Unstimulated bone marrow (BM) and peripheral blood stem cells (PBSC's) were obtained from 85 and 94 donors respectively. The donors of PBSC's were treated with granulocyte-colony-stimulating-factor (10 mg/kg/day) before the donation. 12 Pre-transplant histo-compatibility testing of donors and patients consisted of HLA class I and II typing by allele level PCR single-stranded polymorphism. 13 The majority of patients had an HLAidentical sibling donor or a HLA-A, -B and -DRb1 identical unrelated donor, but 12 with mismatched donors were also included.
Conditioning
Myeloablative conditioning regimens consisted of cyclophosphamide (60 mg/kg daily) for 2 days in combination with either 7.5-10 Gy single dose total body irradiation (TBI) (n ¼ 65), 12 Gy (4 Â 3 Gy) of fractionated TBI (n ¼ 31), or busulfan (1 mg/kg daily) for 4 days (n ¼ 45). 14, 15 Six patients with aplastic anemia received 200 mg/kg of cyclophosphamide and anti-thymocyte globulin (ATG). All patients with unrelated or mismatched donors were treated with ATG (2-5 mg/kg daily) for 2-5 days before transplantation. 16 The reduced intensity conditioning (RIC) was fludarabine (30 mg/m 2 daily) for 3-6 days, combined with 2 Gy TBI (n ¼ 5), 60 mg/kg cyclophosphamide (n ¼ 9) or busulfan (4 mg/kg daily) for 2 days and ATG (2 mg/kg daily) for 4 days (n ¼ 18).
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GVHD prophylaxis
The majority of patients (88%) received cyclosporine (CsA) combined with four doses of methotrexate (MTX) as prophylaxis against GVHD. 20, 21 If GVHD did not occur, CsA was discontinued after 6 months for patients who received a matched unrelated donor (MUD) or mismatched grafts, and 3 months in the case of sibling transplants. No GVHD prophylaxis was used following the four syngeneic transplants. Other protocols included CsA (n ¼ 2), T-cell depletion (n ¼ 3) and CsA combined with either prednisolone (n ¼ 1) or mycofenolate mofetil (n ¼ 12). 18 Four patients received mycofenolate mofetil and tacrolimus.
Supportive care
During the pancytopenic phase, all patients received prophylactic treatment with oral ciprofloxacin (500 mg twice daily), fluconazole (100 mg daily) and nystatin (200 000 IU 4 times daily) until the absolute neutrophil count exceeded 0.5 Â 10 9 /l. During the first six months after engraftment, trimethoprim-sulfametoxazol was administered as prophylaxis against Pneumocystis carinii infection. Patients with a herpes simplex virus IgG that exceeded 10 000 (determined by enzyme-linked immunosorbent assay; ELISA) received oral or intravenous acyclovir prophylaxis during the pancytopenic period.
If patients had a fever, empirical antibiotic therapy was initiated immediately after samples for culture had been obtained. The primary antibiotic regimen used was trimethoprim-sulfamethoxazole combined with an amino glycoside (amikacin) except in patients with known hypersensitivity to sulfonamides. Treatment was adjusted according to bacterial susceptibility as soon as the etiology had been established in cultures. If a patient had an Table 1 Characteristics of patients included in the study of IgG levels after allogeneic hematopoietic stem cell transplantation 22, 23 Definition and treatment of CMV disease after hemopoietic stem cell transplantation have been previously described. 24, 25 To achieve faster engraftment after transplantation, granulocyte colony-stimulating factor was administered to 129 patients until 2001. This treatment ended when an association with increased risk for acute GVHD was found. 26 Definitions Diagnosis and grading of acute and chronic GVHD were performed based on clinical symptoms and/or biopsies according to established criteria. 27, 28 For the diagnosis of bacteremia, at least one positive blood culture was required. Invasive fungal infection was defined as positive blood culture and/or positive cultures from at least two organs for Candida or Aspergillus species. Aspergillus pneumonia was defined as pulmonary infiltrates and positive cultures of bronchoalveolar lavage fluid, sputum or autopsy samples. Patients with serum IgG values below 4 g/l were defined as significantly deficient according to the existing guidelines for antibody-replacement therapy.
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Measurement of IgG Levels Serum samples for measurement of IgG levels were collected 3, 6, 9 and 12 months following hemopoietic stem cell transplantation and then at yearly intervals until 5 years posttransplantation. Serum IgG was analyzed routinely by nephelometry at Karolinska University Laboratory, Department of Clinical Chemistry. Reference levels were 6-15 g/l.
Statistics
Variables related to the patients, donors, disease and transplant were analyzed for their potential prognostic value on overall survival and TRM. Univariate and multivariate Cox proportional hazard regression models were used to identify independent risk factors for death. Relapse and TRM were competing events. For this reason, assessment of factors predicting TRM were based on the proportional hazard model for sub-distribution of competing risk. Univariate and multivariate analyses were performed using Gray's test and the proportional subdistribution hazard regression model developed by Fine and Gray. A stepwise backward procedure was used to construct a set of independent predictors. All predictors with a P-value below 0.10 in the univariate analysis were included in the multivariate analysis. All tests were twosided.
The multiple linear regression method was used in the analysis of factors affecting IgG levels at different time points . Factors tested by univariate analysis were: patient and donor sex and age, sex mismatch, type of donor, 
Results
Reconstitution of IgG levels after SCT IgG levels were not available for every patient at each time point. After SCT, IgG levels increased throughout the study period, especially from 6 to 12 months (Figure 1 ). In 37 patients, only 2 samples were available; 64 patients had 3 samples; 50 patients had 4 samples; and 28 patients had more than 4 samples.
Factors influencing IgG levels after SCT
Multivariate analysis was performed to further evaluate the factors associated with low antibody levels after transplantation. The following variables were included in the model: acute and chronic GVHD, patient age, donor age, HLA mismatch, treatment with ATG and conditioning therapy. Two factors were associated with low IgG levels three months after SCT: acute GVHD grades I-IV (Po0.01) and patient age p30 years (P ¼ 0.015). Six months after SCT acute GVHD grades I-IV (Po0.001), patient age p30 years (Po0.01) and no treatment with ATG (Po0.01) were associated with low IgG levels. One year after SCT, three variables were associated with low IgG levels: acute GVHD grades I-IV (Po0.01); female donor-to-male recipient (P ¼ 0.017); and GVHD prophylaxis with CsA þ MTX (P ¼ 0.026) ( Table 2 , Figures 2a-e) .
IgG levels and its relation to survival and TRM Figure 3 shows IgG levels after SCT and its correlation to survival and TRM. Patients with low IgG levels (o4 g/l), measured twice during the first year after transplantation, exhibited a decreased cumulative proportion of survival and an increased risk of TRM compared to patients with moderately low or normal levels. Multivariate analysis showed that low IgG levels, TBI-based conditioning, acute GVHD grades II-IV and CMV infection were significantly correlated with higher TRM (Table 3) . Factors associated with a lower overall survival were low IgG levels, higher patient age and acute GVHD grades II-IV (Table 3) . Causes of death in the group with low IgG levels were relapse 5(19%), GVHD 1(4%), infection 4(15%) and others 2(8%). Causes of death in the group with normal IgG levels were relapse 26(17%), GVHD 5(3%), infection 7(5%) and others 7(5%). Patients with low IgG levels had a borderline (P ¼ 0.056) significant increased incidence of infections when they died.
Discussion
Following allogenic SCT, the patient undergoes a period of pronounced cellular and humoral immunodeficiency. Although immunological function gradually increases, some patients, particularly those who suffer from GVHD, do not exhibit reconstitution of the immune system. Most of the patients were immunologically competent within 2 years. 2, 4, [31] [32] [33] In this study, IgG levels after SCT increased throughout the study period. Five factors had a negative effect on IgG levels after SCT: acute GVHD, patient age p30 years at the time of transplantation, lack of treatment with ATG, a female donor-to-a male recipient and treatment with CsA and MTX as GVHD prophylaxis. We hypothesize that some of these factors increase GVHD and thereby decrease immunological reconstitution. On multivariate analysis, low IgG levels significantly correlated with higher TRM and inferior survival. These results suggest that a reasonably high level of IgG in peripheral blood after SCT is one important factor for a good outcome post-SCT.
Several serious problems-GVHD, relapse and infections-need to be considered after SCT. Patients who have undergone SCT are very susceptible to viral, bacterial and fungal infections. A way of overcoming the problem of severe infections is to give prophylactic treatment with high doses of IVIG. There are contradictory findings in the literature regarding the beneficial effects of IVIG treatment. 34 IVIG has been shown to have a positive effect on bacterial infections. 35 Some studies suggest that IVIG could have immunomodulatory effects in vivo, a treatment that decreases the risk of acute GVHD post-SCT. 32, 33 Other studies, however, conclude that IVIG treatment after SCT does not significantly affect GVHD or survival. A retrospective clinical evaluation of prophylactic IVIG treatment post-SCT showed that the overall survival was unaffected, but the incidence of death due to infections was lower in the IVIG-treated group. 36 Although fewer patients treated with IVIG compared to non-IVIG-treated patients died due to infections, more IVIG-treated patients died of veno-occlusive disease of the liver. 37 One study concludes that IVIG reduces proliferation of B-lymphocytes and immunoglobulin production by co-ligation of the B-cell antigen receptor and the Fc-g RIIb receptor mediating the Fc receptor off signal. 38 In addition, one study notes that both IgG and IgM profiles become less heterogeneous in patients who have been treated with IVIG after SCT and that this effect persists months to years after the IVIG treatment has been completed. 33 In summary, we think that these earlier studies show both advantages and disadvantages of IVIG treatment.
We believe that our results, showing a strong correlation between persistent low levels of IgG and death after SCT, provide enough evidence to continue examining IVIG treatment after SCT. Do patients with low IgG levels post transplant benefit from IVIG treatment? In previous studies, IVIG was given regardless of IgG levels posttransplant. Our results raise one main question: is it possible that treatment with immunoglobulin during the first year post-SCT can increase survival? The major indication for IVIG treatment is primary immune deficiency, but there are also indications for IVIG treatment in various autoimmune disorders and infections in immunocompromised patients. Our present results suggest an evaluation of IVIG treatment post-SCT for patients with low IgG levels. We have found no evidence that a low IgG level in itself increases mortality. A low IgG level may be a surrogate marker for other adverse prognostic indicators. Nevertheless, our data show that a very strong predicting factor for death after SCT is a low IgG level (o4 g/l) measured twice during the first year after transplantation. To further evaluate the importance of IgG levels after SCT with respect to survival, researchers should conduct a prospective study in patients with low IgG levels post-SCT and examine the benefit of IVIG treatment in that specific patient group.
